Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Baxter
McKesson
Boehringer Ingelheim

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

BONJESTA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Bonjesta, and when can generic versions of Bonjesta launch?

Bonjesta is a drug marketed by Duchesnay and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in thirty-two countries.

The generic ingredient in BONJESTA is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

Drug patent expirations by year for BONJESTA
Drug Prices for BONJESTA

See drug prices for BONJESTA

Recent Litigation for BONJESTA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Duchesnay Inc. v. Mylan Pharmaceuticals Inc.2015-05-13
Michael R Mastro2009-07-10

See all BONJESTA litigation

Pharmacology for BONJESTA
Paragraph IV (Patent) Challenges for BONJESTA
Tradename Dosage Ingredient NDA Submissiondate
BONJESTA TABLET, EXTENDED RELEASE;ORAL doxylamine succinate; pyridoxine hydrochloride 209661 2018-08-28

US Patents and Regulatory Information for BONJESTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Express Scripts
AstraZeneca
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.